NCNA Quote, Financials, Valuation and Earnings

Bicycle Therapeutics PLC has a net margin of -- compared to NuCana PLC's net margin of -1898.43%. NuCana PLC's return on equity of -- beat Bicycle Therapeutics PLC's return on equity of -29.19%.

NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5252.7%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $33.36 which suggests that it could grow by 127.12%. Given that NuCana PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe NuCana PLC is more attractive than Bicycle Therapeutics PLC.

NuCana PLC has a beta of 0.944, which suggesting that the stock is 5.593% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 0.858, suggesting its less volatile than the S&P 500 by 14.196%.

NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend.

NuCana PLC quarterly revenues are --, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $2.7M. NuCana PLC's net income of -$5.9M is higher than Bicycle Therapeutics PLC's net income of -$50.8M. Notably, NuCana PLC's price-to-earnings ratio is -- while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 20.51x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of --.

NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5252.7%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 86.87%. Given that NuCana PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe NuCana PLC is more attractive than Biodexa Pharmaceuticals PLC.

NuCana PLC has a beta of 0.944, which suggesting that the stock is 5.593% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.

NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

NuCana PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. NuCana PLC's net income of -$5.9M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, NuCana PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus 3.87x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Mereo BioPharma Group PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat Mereo BioPharma Group PLC's return on equity of --.

NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5252.7%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.48 which suggests that it could grow by 96.4%. Given that NuCana PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe NuCana PLC is more attractive than Mereo BioPharma Group PLC.

NuCana PLC has a beta of 0.944, which suggesting that the stock is 5.593% less volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.935, suggesting its less volatile than the S&P 500 by 6.519%.

NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.

NuCana PLC quarterly revenues are --, which are smaller than Mereo BioPharma Group PLC quarterly revenues of --. NuCana PLC's net income of -$5.9M is higher than Mereo BioPharma Group PLC's net income of -$15M. Notably, NuCana PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.

TC BioPharm (Holdings) PLC has a net margin of -- compared to NuCana PLC's net margin of --. NuCana PLC's return on equity of -- beat TC BioPharm (Holdings) PLC's return on equity of --.

NuCana PLC has a consensus price target of $64.50, signalling upside risk potential of 5252.7%. On the other hand TC BioPharm (Holdings) PLC has an analysts' consensus of -- which suggests that it could grow by 375.74%. Given that NuCana PLC has higher upside potential than TC BioPharm (Holdings) PLC, analysts believe NuCana PLC is more attractive than TC BioPharm (Holdings) PLC.

NuCana PLC has a beta of 0.944, which suggesting that the stock is 5.593% less volatile than S&P 500. In comparison TC BioPharm (Holdings) PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

NuCana PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TC BioPharm (Holdings) PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana PLC pays -- of its earnings as a dividend. TC BioPharm (Holdings) PLC pays out -- of its earnings as a dividend.

NuCana PLC quarterly revenues are --, which are smaller than TC BioPharm (Holdings) PLC quarterly revenues of --. NuCana PLC's net income of -$5.9M is lower than TC BioPharm (Holdings) PLC's net income of -$2.5M. Notably, NuCana PLC's price-to-earnings ratio is -- while TC BioPharm (Holdings) PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana PLC is -- versus -- for TC BioPharm (Holdings) PLC. Usually stocks with elevated PS ratios are considered overvalued.